2024
Autoimmune hepatitis: Brighton Collaboration case definition and guidelines for data collection, analysis, and presentation of immunisation safety data
Kochhar S, Assis D, Mack C, Izurieta H, Muratori L, Munoz A, Nordenberg D, Gidudu J, Blau E, Vierling J. Autoimmune hepatitis: Brighton Collaboration case definition and guidelines for data collection, analysis, and presentation of immunisation safety data. Vaccine 2024, 42: 1812-1825. PMID: 38368225, DOI: 10.1016/j.vaccine.2024.01.021.Peer-Reviewed Original ResearchAutoimmune hepatitisCase definitionExclusion of alternative diagnosesBrighton CollaborationLevel of diagnostic certaintyBrighton Collaboration case definitionStandardised case definitionsAdverse eventsMiddle-income countriesAlternative diagnosesClinical trialsBackground incidenceSafety dataProcess expertsStudy of safetyClinical case managementDiagnostic certaintyHealthcare accessControl groupData collectionCOVID-19 vaccineExpert consensusCase managementBiochemical testsSystematic review
2023
Research gaps and opportunities in autoimmune hepatitis—Results of the international autoimmune hepatitis group research workshop 2022
Snijders R, Assis D, Oo Y, Sebode M, Taubert R, Willemse J, Tomsin B, Lohse A, Drenth J, Gevers T, Diseases T. Research gaps and opportunities in autoimmune hepatitis—Results of the international autoimmune hepatitis group research workshop 2022. Liver International 2023, 43: 1375-1384. PMID: 37035872, DOI: 10.1111/liv.15573.Peer-Reviewed Original ResearchConceptsInternational Autoimmune Hepatitis GroupAutoimmune hepatitisRare autoimmune liver diseaseMajor unmet clinical needClinical needAdult autoimmune hepatitisAutoimmune Hepatitis GroupAutoimmune liver diseaseLiver-related complicationsHealth-related qualityNew immunomodulatory therapiesInflammatory immune reactionsUnmet clinical needClinical trial designSpecific diagnostic testsQuality of lifeHepatitis groupNonselective immunosuppressionImmunomodulatory therapyLiver diseasePrognostic markerImmune reactionsPatient representativesTrial designCare delivery
2022
Noninvasive biomarkers for the diagnosis and management of autoimmune hepatitis
Harrington C, Krishnan S, Mack CL, Cravedi P, Assis DN, Levitsky J. Noninvasive biomarkers for the diagnosis and management of autoimmune hepatitis. Hepatology 2022, 76: 1862-1879. PMID: 35611859, PMCID: PMC9796683, DOI: 10.1002/hep.32591.Peer-Reviewed Original ResearchConceptsAutoimmune hepatitisNormal serum transaminasesPediatric autoimmune hepatitisFirst-line treatmentAcute liver failureImmune cell phenotypesPredictors of responseHigh clinical valueNovel candidate biomarkersPersonalized therapeutic managementSystemic corticosteroidsCurrent regimensMedication titrationHistological activityMost patientsClinical courseLiver failureLiver injurySerum transaminasesMedication dosingTherapeutic managementUnclear etiologyHepatic fibrosisClinical valueElevated riskMindfulness-based stress reduction may decrease stress, disease activity, and inflammatory cytokine levels in patients with autoimmune hepatitis
Alrabadi LS, Dutton A, Rabiee A, Roberts SJ, Deng Y, Cusack L, Silveira MG, Ciarleglio M, Bucala R, Sinha R, Boyer JL, Assis DN. Mindfulness-based stress reduction may decrease stress, disease activity, and inflammatory cytokine levels in patients with autoimmune hepatitis. JHEP Reports 2022, 4: 100450. PMID: 35434588, PMCID: PMC9011026, DOI: 10.1016/j.jhepr.2022.100450.Peer-Reviewed Original ResearchQuality of lifeMindfulness-based stress reductionInflammatory cytokine levelsDisease activityCytokine levelsAutoimmune hepatitisAlanine aminotransferaseAdult patientsTRIAL REGISTRATIONPeripheral blood cytokine levelsScore improvementMBSR programPilot studyBlood cytokine levelsSerum alanine aminotransferaseClinical trial registrationSignificant dose reductionPerceived stressExploratory pilot studyALT levelsSteroid requirementsStress reductionCytokine mediatorsALT reductionMedication needsPREDICTORS AND OUTCOMES OF BIOLOGIC/IMMUNOSUPPRESSIVE THERAPY FOR PSC-ASSOCIATED IBD
Sayed A, Silveira M, Assis D, Deng Y, Gaidos J, Proctor D, Al-Bawardy B. PREDICTORS AND OUTCOMES OF BIOLOGIC/IMMUNOSUPPRESSIVE THERAPY FOR PSC-ASSOCIATED IBD. Inflammatory Bowel Diseases 2022, 28: s76-s76. DOI: 10.1093/ibd/izac015.124.Peer-Reviewed Original ResearchPrimary sclerosing cholangitisInflammatory bowel diseasePSC-IBDSmall bowel involvementClinical remissionEndoscopic healingIMM groupAutoimmune hepatitisBowel involvementUrsodeoxycholic acidExact testBackground Inflammatory bowel diseaseEpisodes of cholangitisRate of cholangitisThird of patientsUnpaired Student's t-testFisher's exact testT-testSmall molecule therapiesStudent's t-testThiopurine monotherapyImmunosuppressive therapySclerosing cholangitisAdult patientsBiologic therapy
2021
Outcome of COVID‐19 in Patients With Autoimmune Hepatitis: An International Multicenter Study
Efe C, Dhanasekaran R, Lammert C, Ebik B, la Tijera F, Aloman C, Calışkan A, Peralta M, Gerussi A, Massoumi H, Catana AM, Torgutalp M, Purnak T, Rigamonti C, Aldana A, Khakoo N, Kacmaz H, Nazal L, Frager S, Demir N, Irak K, Ellik ZM, Balaban Y, Atay K, Eren F, Cristoferi L, Batıbay E, Urzua Á, Snijders R, Kıyıcı M, Akyıldız M, Ekin N, Carr RM, Harputluoğlu M, Hatemi I, Mendizabal M, Silva M, Idilman R, Silveira M, Drenth JPH, Assis DN, Björnsson E, Boyer JL, Invernizzi P, Levy C, Schiano TD, Ridruejo E, Wahlin S. Outcome of COVID‐19 in Patients With Autoimmune Hepatitis: An International Multicenter Study. Hepatology 2021, 73: 2099-2109. PMID: 33713486, PMCID: PMC8250536, DOI: 10.1002/hep.31797.Peer-Reviewed Original ResearchConceptsSevere COVID-19Chronic liver diseaseAutoimmune hepatitisLiver injuryMulticenter studyCOVID-19Causes of CLDPropensity score-matched cohortSevere COVID-19 outcomesContinuation of immunosuppressionMaintenance of immunosuppressionOutcomes of patientsIntensive care admissionUse of antiviralsInternational multicenter studyCOVID-19 outcomesCOVID-19 diagnosisContinued immunosuppressionCare admissionCause mortalityIndependent predictorsMedian ageLiver diseaseMechanical ventilationRetrospective study
2020
Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases
Mack CL, Adams D, Assis DN, Kerkar N, Manns MP, Mayo MJ, Vierling JM, Alsawas M, Murad MH, Czaja AJ. Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases. Hepatology 2020, 72: 671-722. PMID: 31863477, DOI: 10.1002/hep.31065.Peer-Reviewed Original ResearchConceptsAutoimmune hepatitisLiver diseaseAmerican AssociationPractice guidanceHepatitisDiseaseDiagnosisImmunosuppressive Treatment Regimens in Autoimmune Hepatitis: Systematic Reviews and Meta‐Analyses Supporting American Association for the Study of Liver Diseases Guidelines
Vierling JM, Kerkar N, Czaja AJ, Mack CL, Adams D, Assis D, Manns MP, Mayo MJ, Nayfeh T, Majzoub AMM, Alzuabi MA, Ding J, Haffar S, Murad MH, Alsawas M. Immunosuppressive Treatment Regimens in Autoimmune Hepatitis: Systematic Reviews and Meta‐Analyses Supporting American Association for the Study of Liver Diseases Guidelines. Hepatology 2020, 72: 753-769. PMID: 32500593, DOI: 10.1002/hep.31407.Peer-Reviewed Original ResearchImmunopathogenesis of Autoimmune Hepatitis
Assis DN. Immunopathogenesis of Autoimmune Hepatitis. Clinical Liver Disease 2020, 15: 129-132. PMID: 32257125, PMCID: PMC7128031, DOI: 10.1002/cld.873.Peer-Reviewed Original Research
2019
The Contribution of B Cells in Autoimmune Liver Diseases
Taylor SA, Assis DN, Mack CL. The Contribution of B Cells in Autoimmune Liver Diseases. Seminars In Liver Disease 2019, 39: 422-431. PMID: 31226726, PMCID: PMC6800599, DOI: 10.1055/s-0039-1688751.BooksConceptsAutoimmune liver diseaseT cell activationB cellsLiver diseaseT cellsCell activationB-cell mechanismsRegulatory T cellsProduction of autoantibodiesAutoreactive T cellsAutoreactive B cellsGeneration of cytokinesAutoimmune hepatitisCell mechanismsAntigen presentationDisease pathogenesisAutoantibodiesDiseaseCellsActivationVast majorityHepatitisCholangiopathyAutoimmunityCytokines
2018
Histologic features of autoimmune hepatitis: a critical appraisal
Gurung A, Assis DN, McCarty TR, Mitchell KA, Boyer JL, Jain D. Histologic features of autoimmune hepatitis: a critical appraisal. Human Pathology 2018, 82: 51-60. PMID: 30041025, DOI: 10.1016/j.humpath.2018.07.014.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedBiopsyChildChild, PreschoolDatabases, FactualEmperipolesisFemaleHepatitis C, ChronicHepatitis, AutoimmuneHepatocytesHumansKupffer CellsLiverLiver CirrhosisLymphocytesMaleMiddle AgedPlasma CellsPredictive Value of TestsReproducibility of ResultsRetrospective StudiesSeverity of Illness IndexYoung AdultConceptsProminent plasma cellsAutoimmune hepatitisHistologic featuresPlasma cellsInflammatory gradePortal tractsScoring systemInitiation of therapySeverity of hepatitisDifferent control groupsChronic hepatitisHepatitis CFibrosis stageStudy groupDisease processHepatitisControl groupHyaline globulesFurther studiesPatientsTractCritical appraisalCellsGradeTypical features
2016
A Macrophage Migration Inhibitory Factor Polymorphism Is Associated with Autoimmune Hepatitis Severity in US and Japanese Patients
Assis DN, Takahashi H, Leng L, Zeniya M, Boyer JL, Bucala R. A Macrophage Migration Inhibitory Factor Polymorphism Is Associated with Autoimmune Hepatitis Severity in US and Japanese Patients. Digestive Diseases And Sciences 2016, 61: 3506-3512. PMID: 27696094, PMCID: PMC5106299, DOI: 10.1007/s10620-016-4322-z.Peer-Reviewed Original ResearchMeSH KeywordsAdrenal Cortex HormonesAdultAlanine TransaminaseAntigens, Differentiation, B-LymphocyteAsian PeopleCase-Control StudiesEnzyme-Linked Immunosorbent AssayFemaleGenetic Predisposition to DiseaseHepatitis, AutoimmuneHistocompatibility Antigens Class IIHumansIntramolecular OxidoreductasesJapanMacrophage Migration-Inhibitory FactorsMaleMiddle AgedPolymorphism, GeneticPolymorphism, Single NucleotideSeverity of Illness IndexUnited StatesConceptsMacrophage migration inhibitory factorAIH patientsAutoimmune hepatitisSteroid requirementsMIF expressionMacrophage Migration Inhibitory Factor PolymorphismGC/CC genotypesCC/GCJapanese AIH patientsJapanese patient groupMigration inhibitory factorMultiple autoimmune diseasesGC single nucleotide polymorphismsGC/CCAIH groupHepatitis severityMIF promoterSteroid resistanceMIF genotypeSerum ALTSymptomatic presentationGG patientsHigher ALTClinical parametersMIF polymorphisms
2013
The role of macrophage migration inhibitory factor in autoimmune liver disease
Assis DN, Leng L, Du X, Zhang CK, Grieb G, Merk M, Garcia AB, McCrann C, Chapiro J, Meinhardt A, Mizue Y, Nikolic‐Paterson D, Bernhagen J, Kaplan MM, Zhao H, Boyer JL, Bucala R. The role of macrophage migration inhibitory factor in autoimmune liver disease. Hepatology 2013, 59: 580-591. PMID: 23913513, PMCID: PMC3877200, DOI: 10.1002/hep.26664.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntigens, Differentiation, B-LymphocyteBiomarkersBiopsyCase-Control StudiesCohort StudiesFemaleGene FrequencyHepatitis, AutoimmuneHistocompatibility Antigens Class IIHumansIntramolecular OxidoreductasesLiverLiver Cirrhosis, BiliaryMacrophage Migration-Inhibitory FactorsMaleMicrosatellite RepeatsMiddle AgedPhenotypePolymorphism, Single NucleotideConceptsMacrophage migration inhibitory factorPrimary biliary cirrhosisAutoimmune hepatitisMigration inhibitory factorMIF receptorHealthy controlsInhibitory factorAutoimmune liver diseaseMIF promoter polymorphismsHepatic stellate cellsEnzyme-linked immunosorbentCATT7 alleleImmunopathogenic basisMIF expressionMIF locusBiliary cirrhosisLiver diseaseInflammatory phenotypeReceptor profileStellate cellsPromoter polymorphismPatientsSerum samplesCD74Single nucleotide polymorphisms